Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

H460 lung cancer cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) Akt (6) AMPK (1) Amyloid-β (1) Antibiotic (1) Apoptosis (17) ATM/ATR (1) Autophagy (2) Bacterial (2) Bcl-2 Family (3) Beclin1 (1) c-Myc (2) Carbonic Anhydrase (1) Caspase (2) COX (1) DNA/RNA Synthesis (2) Drug Derivative (1) Drug Metabolite (1) EGFR (1) Endogenous Metabolite (1) ERK (2) FAK (2) Ferroptosis (2) Fungal (1) G-quadruplex (1) GLUT (1) Glutaminase (1) Glutathione Peroxidase (1) Glycosidase (1) GSK-3 (1) HDAC (1) HIF/HIF Prolyl-Hydroxylase (1) Histone Methyltransferase (3) HIV (3) HSP (1) Integrin (2) Interleukin Related (2) JNK (1) Keap1-Nrf2 (3) Liposome (1) MDM-2/p53 (2) Microtubule/Tubulin (1) Mitochondrial Metabolism (2) mTOR (3) NF-κB (2) P-glycoprotein (1) p38 MAPK (2) Parasite (1) PARP (1) PD-1/PD-L1 (1) Phosphatase (1) Phospholipase (1) PI3K (2) PPAR (1) PROTACs (2) Ras (2) Reactive Oxygen Species (ROS) (6) ROR (1) ROS Kinase (1) Src (1) Stearoyl-CoA Desaturase (SCD) (2) STING (1) Tau Protein (1) TNF Receptor (1) Topoisomerase (1) ULK (1) VEGFR (1)
By Research Areas:	Cancer (41) Infection (4) Inflammation/Immunology (4) Metabolic Disease (2) Neurological Disease (2)

By Targets:

11β-HSD (1)

Akt (6)

AMPK (1)

Amyloid-β (1)

Antibiotic (1)

Apoptosis (17)

ATM/ATR (1)

Autophagy (2)

Bacterial (2)

Bcl-2 Family (3)

Beclin1 (1)

c-Myc (2)

Carbonic Anhydrase (1)

Caspase (2)

COX (1)

DNA/RNA Synthesis (2)

Drug Derivative (1)

Drug Metabolite (1)

EGFR (1)

Endogenous Metabolite (1)

ERK (2)

FAK (2)

Ferroptosis (2)

Fungal (1)

G-quadruplex (1)

GLUT (1)

Glutaminase (1)

Glutathione Peroxidase (1)

Glycosidase (1)

GSK-3 (1)

HDAC (1)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Methyltransferase (3)

HIV (3)

HSP (1)

Integrin (2)

Interleukin Related (2)

JNK (1)

Keap1-Nrf2 (3)

Liposome (1)

MDM-2/p53 (2)

Microtubule/Tubulin (1)

Mitochondrial Metabolism (2)

mTOR (3)

NF-κB (2)

P-glycoprotein (1)

p38 MAPK (2)

Parasite (1)

PARP (1)

PD-1/PD-L1 (1)

Phosphatase (1)

Phospholipase (1)

PI3K (2)

PPAR (1)

PROTACs (2)

Ras (2)

Reactive Oxygen Species (ROS) (6)

ROR (1)

ROS Kinase (1)

Src (1)

Stearoyl-CoA Desaturase (SCD) (2)

STING (1)

Tau Protein (1)

TNF Receptor (1)

Topoisomerase (1)

ULK (1)

VEGFR (1)

By Research Areas:

Cancer (41)

Infection (4)

Inflammation/Immunology (4)

Metabolic Disease (2)

Neurological Disease (2)

Inhibitors & Agonists

Peptides

Natural
Products

Targets Recommended: Nuclear Factor of activated T Cells (NFAT) BCRP TREM receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P11115

CIGB-552	Apoptosis NF-κB Reactive Oxygen Species (ROS)	Inflammation/Immunology Cancer
CIGB-552 is a cell-penetrating peptide with anti-tumor properties with the IC₅₀ of 23 μM in H460 cells. CIGB-552 can increase the level of protein COMMD1. CIGB-552 significantly inhibits the NF-κB signaling pathway. CIGB-552 can promote apoptosis of the tumor cells. CIGB-552 can induce the accumulation of reactive oxygen species (ROS) in tumor cells. CIGB-552 has anti-inflammatory and anti-angiogenic effects. CIGB-552 can be used for the research of the lung cancer and colon cancer.

HY-137497

KRAS inhibitor-9	Ras Apoptosis	Cancer
KRAS inhibitor-9, a potent KRAS inhibitor (K_d=92 μM), blocks the formation of GTP-KRAS and downstream activation of KRAS. KRAS inhibitor-9 binds to KRAS G12D, KRAS G12C and KRAS Q61H protein with a moderate binding affinity. KRAS inhibitor-9 causes G2/M cell cycle arrest and induces apoptosis. KRAS inhibitor-9 selectively inhibits the proliferation of NSCLC cells with KRAS mutation but not normal lung cells .

HY-N0660

Jujuboside B	Apoptosis PARP Caspase AMPK Autophagy VEGFR Keap1-Nrf2 STING 11β-HSD Ferroptosis PI3K Akt p38 MAPK ERK	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM_2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes .

HY-153873

MSU38225	Keap1-Nrf2 Reactive Oxygen Species (ROS)	Cancer
MSU38225 is a selective Nrf2 inhibitor. MSU38225 increases ROS levels by inhibiting antioxidant production. MSU38225 arrests cells at the G₂/M phase, enhances cellular sensitivity to chemotherapeutic agents, and exerts synergistic effects with Carboplatin (HY-17393) and 5-fluorouracil (HY-90006). MSU38225 exhibits anticancer activity against lung cancer. MSU38225 can be used in research related to non-small cell lung cancer .

HY-17026A

Gemcitabine triphosphate dFdCTP	Drug Metabolite DNA/RNA Synthesis Apoptosis	Cancer
Gemcitabine triphosphate (dFdCTP) is the active metabolite of Gemcitabine (HY-17026). The mechanism of Gemcitabine triphosphate cell-killing is its competition with cytidine triphosphate during DNA replication, which results in the inhibition of chain elongation. Gemcitabine triphosphate shows a K_i of 11.2 μM against DNA polymerase α and 14.4 μM against DNA polymerase ε. Gemcitabine triphosphate partially inhibits dCMP deaminase and acts as a substrate for DNA synthesis to incorporate into cellular DNA and RNA. Gemcitabine triphosphate disrupts DNA and RNA synthesis, arrests cell cycle in G0/G1 and S phases, triggers apoptosis, reduces tumor cell proliferation. Gemcitabine triphosphate can be used for the research of pancreatic cancer and non-small cell lung cancer .

HY-N10549

Gigantol 1 Publications Verification	Ferroptosis c-Myc Glutathione Peroxidase JNK Reactive Oxygen Species (ROS) GSK-3	Infection Metabolic Disease Cancer
Gigantol is an orally active bibenzyl compound. Gigantol targets MYC to promote its ubiquitin-proteasomal degradation and inhibit the growth of lung cancer cells. Gigantol exerts anti-lung cancer activity by inducing ferroptosis (Ferroptosis) via the SLC7A11-GPX4 axis. Gigantol restores the sensitivity of mcr-harboring multidrug-resistant bacteria to colistin. Gigantol ameliorates carbon tetrachloride-induced liver injury by inhibiting the activation of the JNK/cPLA2/12-LOX inflammatory pathway. Gigantol promotes cholesterol metabolism and progesterone biosynthesis in Leydig cells. Gigantol can be used in studies related to diseases such as lung cancer, multidrug-resistant Gram-negative bacterial infections, and acute liver injury .

HY-168566

EV206	HSP	Cancer
EV206 is a Hsp70 binder and apoptosis inducer that binds to the N-terminal domain of Hsp70, promotes Hsp70 degradation via the ubiquitin-proteasome system, and reduces Hsp70 protein stability. EV206 induces apoptotic cell death, inhibits colony formation, and downregulates the expression of cancer stem cell-related markers in non-small cell lung cancer cells. EV206 inhibits the growth of H460 xenograft tumors in nude mice and can be used for the research of non-small cell lung cancer .

HY-142095

NSD3-IN-3	Histone Methyltransferase	Cancer
NSD3-IN-3 is a potent NSD3 inhibtor with an IC₅₀ value of 1.86 μM. NSD3-IN-3 has anticancer activity and significantly inhibits the growth and proliferation of non-small cell lung cancer cell line H460 .

HY-113638

CVT-11127 GS-456332	Stearoyl-CoA Desaturase (SCD) Apoptosis	Cancer
CVT-11127 is a potent SCD inhibitor. CVT-11127 induces apoposis and arrests the cell cycle at the G1/S phase. CVT-11127 has the potential for the research of lung cancer .

HY-145312

ATR-IN-4	ATM/ATR	Cancer
ATR-IN-4 is a potent ATR (Ataxia telangiectasia mutated gene Rad 3-associated kinase) inhibitor. ATR-IN-4 inhibits growth of human prostate cancer cells DU145 and human lung cancer cells NCI-H460 with IC₅₀s of 130.9 nM and 41 .33 nM, respectively. (Patent CN112142744A, compound 13) .

HY-162753

ZW-1226	P-glycoprotein	Cancer
ZW-1226 is a dual Tyrosyl DNA phosphodiesterase 2 (TDP2) and Multidrug resistance-associated protein 1 (MRP1) inhibitor with IC₅₀ values of 0.2 and 0.5 μM, respectively. ZW-1226 exhibits selectivity over other ABC transporters. ZW-1226 elevates intracellular GSH levels, and reverses MRP1-mediated drug resistance. ZW-1226 can be used for the research of leukemia, non-small-cell lung cancer, and multidrug resistant small-cell lung cancer .

HY-121811

Pongamol Lanceolatin C	Glycosidase Phosphatase Interleukin Related TNF Receptor COX Beclin1 GLUT FAK Akt mTOR p38 MAPK Keap1-Nrf2 Apoptosis Amyloid-β Tau Protein Autophagy	Neurological Disease Inflammation/Immunology Cancer
Pongamol (Lanceolatin C) is an orally active flavonoid with an IC₅₀ of 75 μM and a K_i of 58 μM against PTPase-1B, and an IC₅₀ of 103.5 μM against intestinal α-Glycosidase. Pongamol reduces the release of IL‑1β, TNF‑α, COX‑2 and iNOS in cells, reverses the nuclear translocation of NF‑κB, and upregulates the levels of Beclin 1 and LC3 Ⅱ/LC3 Ⅰ. Pongamol promotes glucose uptake by increasing the level of GLUT4 on the surface of skeletal muscle cells. Pongamol inhibits epithelial-mesenchymal transition by suppressing the FAK/Akt-mTOR signaling pathway. Pongamol inhibits neuronal cytotoxicity, suppresses cell apoptosis and extends the lifespan of Caenorhabditis elegans by activating the MAPKs/Nrf2 signaling pathway. Pongamol exerts hypoglycemic effects in diabetic mouse models. Pongamol exhibits antibacterial activity. Pongamol alleviates oxidative stress, neuroinflammation, Aβ deposition and excessive phosphorylation of Tau Protein, and restores autophagy function in Alzheimer's disease mouse models by inhibiting the Akt/mTOR signaling pathway. Pongamol is applicable to research related to Alzheimer's disease, type 2 diabetes, non-small cell lung cancer and postprandial hyperglycemia .

HY-161313

DYB-03	Histone Methyltransferase HIF/HIF Prolyl-Hydroxylase	Cancer
DYB-03 is an oral active HIF-1α/EZH2 inhibitor. DYB-03 inhibits migration, invasion, and angiogenesis of lung cancer cells and HUVECs in vitro and in vivo. DYB-03 induces apoptosis in 2-ME2 ^- and GSK126 ^-resistant of A549 and H460 cells .

HY-N0867

13-Oxyingenol-13-dodecanoate	HIV ULK Bcl-2 Family	Infection Cancer
13-Oxyingenol-dodecanoate (13OD) is a tumor suppressor agent. 13-Oxyingenol-dodecanoate has anti-HIV-1 activity with EC₅₀ value of 33.7 nM .13-Oxyingenol-dodecanoate can induce the expression of ULK1 to effect mitochondrial dysfunction and cellular autophagy. 13-Oxyingenol-dodecanoate also increases the expression of BAX and suppresses the expression of BCL-2 to effect apoptosis .

HY-142094

NSD3-IN-2	Histone Methyltransferase	Cancer
NSD3-IN-2 is a potent NSD3 inhibitor with an IC₅₀ value of 17.97 μM. NSD3-IN-2 inhibits the growth and proliferation of non-small cell lung cancer cell lines H460, H1299 and H1650 with anti-cancer activity .

HY-123298

Chrysotoxine 1 Publications Verification	Src Akt Apoptosis	Cancer
Chrysotoxine is a dual inhibitor of Src/Akt. Chrysotoxine suppresses cancer stem cells (CSCs) phenotypes by down-regulating Src/Akt signaling. Chrysotoxine reduces cell viability and increases apoptosis level in H460 and H23 cells instead of non-tumor cell lines. Chrysotoxine shows rapid excretion and low bioavailability in rats. Chrysotoxine is used in cancer research .

HY-P10988

LVTX-8	Apoptosis MDM-2/p53 Integrin	Cancer
LVTX-8 is a peptide toxin, exacted from Lycosa vittata. LVTX-8 has potent anticancer and and anti-metastasis activities towards lung cancer with strong cytotoxicity. LVTX-8 significantly induces apoptosis and inhibits the proliferation, invasion and migration of lung cancer cells through P53 hypoxia pathways and integrin signaling. LVTX-8 significantly inhibits the tumor growth and metastasis in A549/H460 xenograft mice model .

HY-124084

SW203668	Stearoyl-CoA Desaturase (SCD)	Cancer
SW203668 is an irreversible stearoyl CoA desaturase (SCD) inhibitor with an IC₅₀ of 54 nM. SW203668 covalently binds and inhibits SCD, depletes unsaturated fatty acids, and triggers cell death in sensitive cells. SW203668 requires demethylation by CYP4F11 to form its active SCD-inhibiting form; differential CYP4F11 expression drives selective cytotoxicity. SW203668 exerts cytotoxicity toward CYP4F11-expressing non-small cell lung cancer (NSCLC) cells and spares CYP4F11-lacking NSCLC cells. SW203668 inhibits tumor growth in immunodeficient mice bearing CYP4F11-expressing NSCLC xenografts and spares mouse skin sebocytes. SW203668 can be used for the research of non-small cell lung cancer .

HY-170995

PROTAC ROR1 degrader-1	PROTACs ROR Apoptosis	Cancer
PROTAC ROR1 degrader-1 is a ROR1 PROTAC degrader with DC₅₀ values of 40.88 nM (NCI-H23), 69.0 nM (NCI-H460), 83.35 nM (NCI-H1299) and 42.07 nM (NCI-H1975), respectively. PROTAC ROR1 degrader-1 inhibits the proliferation of lung cancer cells and induces apoptosis. PROTAC ROR1 degrader-1 can be used in research related to non-small cell lung cancer .

HY-N15267

Ovalitenone	FAK Akt mTOR	Cancer
Ovalitenone is a flavonoid compound that can be isolated from the plant Millettia peguensis. It shows no cytotoxic effects on lung cancer H460 and A549 cells, but it significantly inhibits anchorage-independent growth, CSC-like phenotypes, colony formation, and the migration and invasion capabilities of cancer cells. Ovalitenone can significantly reduce the levels of N-cadherin, snail, and slug, while increasing E-cadherin, thus inhibiting the EMT pathway. Additionally, Ovalitenone suppresses the signaling pathways regulated by focal adhesion kinase (FAK), ATP-dependent tyrosine kinase (AKT), mammalian target of rapamycin (mTOR), and cell division cycle 42 (Cdc42) .

HY-P11115A

CIGB-552 TFA	Apoptosis NF-κB Reactive Oxygen Species (ROS)	Cancer
CIGB-552 TFA is a cell-penetrating peptide with anti-tumor properties with the IC₅₀ of 23 μM in H460 cells. CIGB-552 TFA can increase the level of protein COMMD1. CIGB-552 TFA significantly inhibits the NF-κB signaling pathway. CIGB-552 TFA can promote apoptosis of the tumor cells. CIGB-552 TFA can induce the accumulation of reactive oxygen species (ROS) in tumor cells. CIGB-552 TFA has anti-inflammatory and anti-angiogenic effects. CIGB-552 TFA can be used for the research of the lung cancer and colon cancer.

HY-P11102

Temporin-SHa	Bacterial Fungal HIV Parasite	Infection Cancer
Temporin-Sha is an antibacterial peptide with extensive biological activity. Temporin-Sha exhibits broad-spectrum antibacterial activity (e.g., against L. ivanovii, MIC = 6.25 μM), and is effective against Gram-negative bacteria (such as Escherichia coli, MIC = 10 μM), including drug-resistant strains (such as Methicillin (HY-121544)-resistant Staphylococcus aureus). Temporin-Sha also has inhibitory effects on Candida albicans (MIC = 25 μM), Saccharomyces cerevisiae (MIC = 12 μM), the pre-flagellated and non-flagellated forms of Leishmania infantum (IC₅₀ = 5-20 μM), and Trypanosoma cruzi (IC₅₀ = 17 μM). Temporin-Sha exhibits antiviral activity against HSV-1 and has anti-cancer effects (cytotoxicity against breast cancer cells MCF-7 and lung cancer cells H460, etc.) .

HY-164033

HOE 689 Ramnodigin	Apoptosis	Cancer
HOE 689 (Ramnodigin) is an analog of Digitoxin (HY-B1357). HOE 689 exhibits cytotoxicity to lung cancer cells and induces apoptosis in cancer cell NCI-H460 with an IC₅₀ of 52 nM .

HY-126803

Saquayamycin B	Antibiotic	Infection Cancer
Saquayamycin B (compound 3) is a new angucycline antibiotic. Saquayamycin B has antitumor activities against a human lung (H-460) and a human breast cancer cell line (MCF-7) with GI₅₀ values of 12.2 and 15.2 µM respectively .

HY-122552

Chrysotobibenzyl	Integrin	Cancer
Chrysotobibenzyl can be isolated from stem of Dendrobium pulchellum. Chrysotobibenzyl inhibits lung cancer cell (H460 and H292) migration, invasion, filopodia formation via Cav-1, integrins β1, β3, and αν, and EMT suppressions. Chrysotobibenzyl also sensitizes lung cancer cell death mediated by Cisplatin (HY-17394) .

HY-155522

WES-1	Carbonic Anhydrase	Cancer
WES-1 (Compound 8g) is an inhibitor of carbonic anhydrase IX (K_i: 55.9 μM). WES-1 has broad spectrum anti-proliferative activity against the cancer cells, such as leukemia (K-562 and MOLT-4), non-small cell lung cancer (NCI–H460), colon cancer (HCT 116 and HCT-15) and melanoma (LOX IMVI) cell lines .

HY-138098

Sartorypyrone B	Endogenous Metabolite	Cancer
Sartorypyrone B is a 2β-acetoxyl analogue of chevalone C. Sartorypyrone B is yielded from the ethyl acetate extract of the culture of the marine sponge-associated fungus Neosartorya tsunodae (KUFC 9213). Sartorypyrone B exhibits strong growth inhibitory activity, having GI₅₀s of 17.8, 20.5, and 25.0 μM, respectively, for MCF-7, NCI-H460, and A375-C5. Sartorypyrone B has the potential for the research of breast adenocarcinoma, non-small cell lung cancer, and melanoma diseases .

HY-169262

PLD-IN-1	Phospholipase Apoptosis	Cancer
PLD-IN-1 (Compound 3r) is an orally active inhibitor for phospholipase D with an IC₅₀ of 1.97 μM. PLD-IN-1 reduces the expression of CD24, CD47 and PD-L1, enhances the calreticulin expression, and thus modulates the immune evasion mechanism in lung cancer cells by promoting the phagocytosis of cancer cells by macrophages. PLD-IN-1 inhibits the cell viability of lung cancer cell A549, HCC44, H460 and HCC15 with IC₅₀ of 18.44, 22.31, 24.85 and 21.45 μM, respectively. PLD-IN-1 can induce apoptosis and inhibits migration in cell A549. PLD-IN-1 enhances the level of pro-inflammatory M1 macrophages and decreases the level of anti-inflammatory M2 macrophages, exhibits antitumor efficacy in mouse model .

HY-139090

3-Oxobetulin acetate 28-O-Acetyl-3-Oxobetulin; 3-oxo-28-O-Acetylbetulin	Bacterial HIV Drug Derivative	Cancer
3-Oxobetulin acetate (28-O-Acetyl-3-Oxobetulin; 3-oxo-28-O-Acetylbetulin) is a derivative of betulin (HY-N0083), a cholesterol biosynthesis inhibitor. 3-Oxobetulin acetate inhibits the growth of P388 murine lymphocytic leukemia cells (EC50=0.12 μg/mL) and human MCF-7 breast cancer, SF-268 CNS cancer, H460 lung cancer, and KM20L2 colon cancer cells (GI50s=8, 10.6, 5.2, and 12.7 μg/mL), but not BxPC-3 pancreatic cancer cells or DU145 prostate cancer cells (GI50s=>10 μg/mL for both). 3-Oxobetulin acetate inhibits the replication of X4-tropic recombinant HIV (NL4.3-Ren) in MT-2 lymphoblastoid cells (IC50=13.4 μM). 3-Oxobetulin acetate is also effective against Listeria donovani amastigotes.

HY-179321

PROTAC HDAC4 Degrader-1	PROTACs HDAC	Cancer
PROTAC HDAC4 Degrader-1 (compound SCT-1) is a potent and selective PROTAC HDAC4 degrader. PROTAC HDAC4 Degrader-1 reduces HDAC4 protein level, induces S phase cell cycle arrest, and inhibits cell colony formation, thereby inhibiting proliferation of the tumor cells. PROTAC HDAC4 Degrader-1 exhibits efficacy in a H460 mouse model. PROTAC HDAC4 Degrader-1 can be used for cancer research, such as lung cancer .

HY-118988

CAY10506	PPAR Apoptosis	Cancer
CAY10506 is a PPARγ ligand that can induce cell death and ROS production in a PPARγ-dependent manner in vitro. CAY10506 exhibits radiosensitizing effects, enhancing γ-radiations-induced apoptosis and caspase-3-mediated poly (ADP-ribose) polymerase (PARP) cleavage. CAY10506 can be used in cancer research .

HY-180562

KARS-IN-1	Ras	Cancer
KARS-IN-1 (152) is a AKR1C3 dependent KARS inhibitor with an AC₅₀ of 9.1 nM for human KARS. KARS-IN-1 shows anti-proliferative activity in H460 (NRF2 pathway mutant cell line with high AKR1C3 expression) and Hara (NRF2 pathway wild type cell line with low AKR1C3 expression), with AC₅₀ values ??of 21 nM and 16 nM, respectively. KARS-IN-1 can be used for the study of non-small cell lung cancer (NSCLC) .

HY-150571

Anticancer agent 76	Topoisomerase c-Myc Apoptosis ROS Kinase	Cancer
Anticancer agent 76 (Compound CT2-3) is an anticancer agent. Anticancer agent 76 significantly inhibits the proliferation of human NSCLC cells, induces cell cycle arrest, causes ROS generation and induces cell apoptosis .

HY-158969

EGFR-IN-113	EGFR Apoptosis Akt ERK	Cancer
EGFR-IN-113 (compound II-1) is an EGFR kinase inhibitor with an IC₅₀ of 14.79 μM. EGFR-IN-113 can induce apoptosis and inhibit cell proliferation by downregulating Akt and Erk1/2 signaling. EGFR-IN-113 can be used for research in EGFR-driven cancers, such as lung cancer, pancreatic cancer, and breast cancer .

HY-181890

TRG-192	Glutaminase	Cancer
TRG-192 is a potent and selective glutaminase (GLS) inhibitor with an IC₅₀ of 68 nM. TRG-192 inhibits intracellular glutamate levels. TRG-192 is applicable to related research on non-small cell lung cancer .

HY-183327

PI3K/mTOR-IN-22	PI3K mTOR Akt Apoptosis Reactive Oxygen Species (ROS) Mitochondrial Metabolism Bcl-2 Family Caspase	Cancer
PI3K/mTOR-IN-22 is an orally active PI3K/mTOR kinase dual inhibitor with IC₅₀ values of 400.5 nM and 8.2 nM. PI3K/mTOR-IN-22 downregulates phosphorylation of the AKT and mTOR, upregulates pro-apoptotic proteins Bax and caspase-3 and downregulates anti-apoptotic protein Bcl-2. PI3K/mTOR-IN-22 exhibits antiproliferative activity against cancer cells, induces apoptosis and ROS production, and reduces mitochondrial membrane potential. PI3K/mTOR-IN-22 exhibits antitumor activity in breast cancer mice models .

HY-183984

G-quadruplex ligand 6	G-quadruplex	Cancer
G-quadruplex ligand 6 is a G-quadruplex ligand targeting the c-MYC promoter with anti-tumor activity. G-quadruplex ligand 6 forms a non-covalent complex with Pu22, a G-quadruplex model of the c-MYC promoter, with a microscopic dissociation constant K_d of 0.202 μM. G-quadruplex ligand 6 selectively inhibits tumor cell proliferation, blocks the binding of transcription factors by stabilizing the G-quadruplex in the c-MYC promoter, and thereby regulates the expression of proto-oncogenes. G-quadruplex ligand 6 can be used in the research of pancreatic cancer, non-small cell lung cancer, colorectal cancer, and triple-negative breast cancer .

HY-184443

Bcl-2-IN-26	Microtubule/Tubulin Bcl-2 Family Apoptosis MDM-2/p53 Mitochondrial Metabolism Reactive Oxygen Species (ROS)	Cancer
Bcl-2-IN-26 is an inhibitor targeting β-tubulin and BCL-2. Bcl-2-IN-26 disrupts the intracellular microtubule network and interferes with cell mitosis, inducing G2/M phase cell cycle arrest. Bcl-2-IN-26 suppresses antiapoptotic BCL-2 function via p53 upregulation, thereby triggering mitochondrial dysfunction, elevated ROS production and robust tumor cell apoptosis. Bcl-2-IN-26 can be used in lung cancer research ^[1]

HY-P11143A

IL4RPep-1 acetate 1 Publications Verification	Interleukin Related Liposome	Cancer
IL4RPep-1 acetate is an interleukin-4 receptor (IL-4R) binding agent. IL4RPep-1 acetate preferentially binds to cells with high levels of IL-4R expression compared to those with low levels of expression. IL4RPep-1-labeled liposomes containing Doxorubicin (HY-15142A) are internalized by cells more efficiently. IL4RPep-1-labeled liposomes accumulate more effectively within H226 tumors .

HY-171171

NERx 329	DNA/RNA Synthesis	Cancer
NERx 329 is a replication protein A (RPA) inhibitor with an IC₅₀ of 4.9 μM. NERx 329 blocks the interaction between RPA and single-stranded DNA, and induces functional RPA depletion, loss of single-stranded DNA gap protection, chromosome fragmentation and cell death. NERx 329 inhibits the DNA damage response signaling pathway, exhibits broad single-agent anticancer activity, and enhances the activity of DNA-damaging agents. NERx 329 can be used in research related to brca1-deficient breast cancer, non-small cell lung cancer, and brca1-deficient ovarian cancer .

HY-184300

PDL1 degrader-4	PD-1/PD-L1	Inflammation/Immunology Cancer
PDL1 degrader-4 is a PD-L1 degrader that induces PD-L1 degradation via the LAMP2-mediated lysosomal pathway, with a K_d value of 5.58 μM. PDL1 degrader-4 induces anti-tumor immunity through PD-L1 degradation. PDL1 degrader-4 is applicable to research related to non-small cell lung cancer .

Cat. No.	Product Name	Target	Research Area